Zhou Hanyu, Yun Xiao, Shu Yongqian, Xu Kequn
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Department of Oncology, Gusu School, Nanjing Medical University, Suzhou, Jiangsu 215006, P.R. China.
Oncol Lett. 2023 Feb 1;25(3):101. doi: 10.3892/ol.2023.13687. eCollection 2023 Mar.
Gemcitabine is regarded as a standard medication for patients with pancreatic cancer. The aim of the present study was to investigate the impact of aspirin (ASA) on the efficacy of gemcitabine in pancreatic cancer and the potential mechanism. The SW1990 and BxPC-3 human pancreatic cell lines were treated with 2 mmol/l ASA and/or 1 mg/l gemcitabine. The effects of the treatments were tested on the viability, migration and invasion of the cells using MTT, wound healing and Transwell invasion assays. In addition, cell apoptosis was evaluated via flow cytometry with Annexin V-FITC/PI and the western blotting of Bax and Bcl-2. The expression of epithelial-mesenchymal transition (EMT)-associated proteins and activation of the PI3K/AKT/mTOR pathway were also assessed using western blotting. The results reveal that ASA increased the efficacy of gemcitabine in reducing the proliferation, migration and invasion of pancreatic cancer cells and increasing their apoptosis. These effects are associated with inhibition of the PI3K/AKT/mTOR pathway and the reversal of EMT. Thus, the combined use of ASA and gemcitabine is suggested to be a potential therapeutic strategy for patients with pancreatic cancer.
吉西他滨被视为胰腺癌患者的标准用药。本研究的目的是探讨阿司匹林（ASA）对吉西他滨治疗胰腺癌疗效的影响及其潜在机制。用2 mmol/l ASA和/或1 mg/l吉西他滨处理SW1990和BxPC-3人胰腺癌细胞系。采用MTT法、伤口愈合实验和Transwell侵袭实验检测处理对细胞活力、迁移和侵袭的影响。此外，通过Annexin V-FITC/PI流式细胞术以及Bax和Bcl-2的蛋白质印迹法评估细胞凋亡。还使用蛋白质印迹法评估上皮-间质转化（EMT）相关蛋白的表达和PI3K/AKT/mTOR通路的激活。结果显示，ASA增强了吉西他滨降低胰腺癌细胞增殖、迁移和侵袭以及增加其凋亡的疗效。这些作用与PI3K/AKT/mTOR通路的抑制和EMT的逆转有关。因此，建议ASA与吉西他滨联合使用是胰腺癌患者的一种潜在治疗策略。
